ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Francesca Lorenzin¹, Giulia Fracassi¹, Federico Vannuccini¹, Mazlina Ismail², Yari Ciani¹, Riccardo Bevilacqua¹, Paola Gasperini¹, Francesco G Carbone³, Sebastiano Cinalli³, Emily Grist², Wout Devlies⁴, Alexander Giesen⁴, Jasper Van Goubergen⁴, Frank Claessens⁴, Steven Joniau⁵, Elai Davicioni⁶, Mattia Barbareschi³, David S Rickman⁷, Andrea Lunardi⁸, Gerhardt Attard², Amina Zoubeidi⁹, Francesca Demichelis¹

¹University of Trento Trento Italy.

²University College London London United Kingdom.

³Ospedale Santa Chiara Trento Italy.

⁴KU Leuven Leuven Belgium.

⁵University Hospitals Leuven Leuven Belgium.

⁶Veracyte (United States) San Diego, California United States.

⁷Weill Cornell Medicine New York, NY United States.

⁸University of Trento Trento, Trento Italy.

⁹University of British Columbia Vancouver, British Colombia Canada.

PubMed DOI

Abstract

ERG fusions occur in about 50% of prostate cancers (PCa) and represent early somatic events that co-initiate tumorigenesis. Yet, the molecular programs unleashed by ERG at disease onset remain elusive. Here, the inducible, temporally controlled expression of ERG enabled the accurate mapping of early ERG-driven processes associated with an apparent decrease in cell fitness across a panel of prostat…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.